BioCentury | May 25, 2018
Clinical News

Genosco reports Phase I/II data for EGFR TKI in NSCLC

...abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. In 2015, Genosco...
...commercialize YH25448, a third-generation TKI targeting activating EGFR mutations and the T790M EGFR resistance mutation. Genosco...
...intracranial response and intracranial PFS Status: Phase I/II data Milestone: NA Chris Lieu YH25448 American Society of Clinical Oncology ASCO Genosco Yuhan...
BioCentury | Feb 26, 2015
Targets & Mechanisms

A LRRKing safety problem

...an established AML target. Ho-Juhn Song, director of biology and strategic alliances at kinase-focused Genosco...
...and dopamine homeostasis in the substantia nigra, a region of the brain affected in PD. Genosco...
...the discovery of additional targets. Companies and Institutions Mentioned Genentech Inc., South San Francisco, Calif. Genosco...
BioCentury | Oct 16, 2014
Distillery Techniques

Technology: Assays & screens

...showed poor stability. Next steps could include screening for derivatives with better in vivo stability. Genosco's...
BioCentury | Mar 27, 2014
Distillery Therapeutics

Indication: Cancer

...toxicity testing of G-749 and starting a Phase I trial in patients with FLT3-mutant AML. Genosco's...
...al. Blood; published online Feb. 14, 2014; doi:10.1182/blood-2013-04-493916 Contact: Ho-Juhn Song, Genosco, Cambridge, Mass. e-mail: hsong@genosco.com BC...
Items per page:
1 - 4 of 4
BioCentury | May 25, 2018
Clinical News

Genosco reports Phase I/II data for EGFR TKI in NSCLC

...abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. In 2015, Genosco...
...commercialize YH25448, a third-generation TKI targeting activating EGFR mutations and the T790M EGFR resistance mutation. Genosco...
...intracranial response and intracranial PFS Status: Phase I/II data Milestone: NA Chris Lieu YH25448 American Society of Clinical Oncology ASCO Genosco Yuhan...
BioCentury | Feb 26, 2015
Targets & Mechanisms

A LRRKing safety problem

...an established AML target. Ho-Juhn Song, director of biology and strategic alliances at kinase-focused Genosco...
...and dopamine homeostasis in the substantia nigra, a region of the brain affected in PD. Genosco...
...the discovery of additional targets. Companies and Institutions Mentioned Genentech Inc., South San Francisco, Calif. Genosco...
BioCentury | Oct 16, 2014
Distillery Techniques

Technology: Assays & screens

...showed poor stability. Next steps could include screening for derivatives with better in vivo stability. Genosco's...
BioCentury | Mar 27, 2014
Distillery Therapeutics

Indication: Cancer

...toxicity testing of G-749 and starting a Phase I trial in patients with FLT3-mutant AML. Genosco's...
...al. Blood; published online Feb. 14, 2014; doi:10.1182/blood-2013-04-493916 Contact: Ho-Juhn Song, Genosco, Cambridge, Mass. e-mail: hsong@genosco.com BC...
Items per page:
1 - 4 of 4